MARKET

TNXP

TNXP

Tonix Pharmaceut
NASDAQ
0.1590
+0.0020
+1.27%
Opening 14:42 04/19 EDT
OPEN
0.1503
PREV CLOSE
0.1570
HIGH
0.1630
LOW
0.1500
VOLUME
892.66K
TURNOVER
0
52 WEEK HIGH
3.688
52 WEEK LOW
0.1202
MARKET CAP
15.19M
P/E (TTM)
-0.0232
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at TNXP last week (0408-0412)?
Weekly Report · 4d ago
WHO's Tedros Adhanom Ghebreyesus Posts On X "In #DRC alone, more than 4500 cases of #mpox and almost 300 deaths have been reported this year. That is triple the number reported at this time last year. The recent surge in cases and deaths among children is of particular concern, along with the re-emergence of Clade One in central Africa...."
Benzinga · 04/11 14:09
Analysts Are Bullish on These Healthcare Stocks: Tonix Pharma (TNXP), OrganiGram Holdings (OGI)
TipRanks · 04/11 12:02
Weekly Report: what happened at TNXP last week (0401-0405)?
Weekly Report · 04/08 11:36
TNXP Stock Earnings: Tonix Pharmaceuticals Beats EPS, Misses Revenue for Q4 2023
Tonix Pharmaceuticals reported earnings per share of -86 cents for the fourth quarter of 2023. The company reported revenue of $3.78 million. This was 1.33% worse than the analyst estimate for revenue. Tonix reported results for the quarter of 1923.
Investorplace · 04/02 03:52
Tonix Pharmaceuticals Holding Corp reports results for the quarter ended in December - Earnings Summary
Tonix Pharmaceuticals Holding Corp reports results for the quarter ended in December. The company reported a quarterly adjusted loss of 86 cents per share. Revenue was $3.78 million; analysts expected a loss of $27.32 million. The shares of Tonix Holding Corp have lost 53.8% this year.
Reuters · 04/01 22:09
Tonix Pharmaceuticals GAAP EPS of -$0.86, revenue of $3.78M
Tonix Pharmaceuticals Holding Corp. Reported Q4 GAAP EPS of -$0.86, revenue of $3.78M. As of December 31, 2023, Tonix had approximately $24.9 million of cash and cash equivalents. The company had inventory of $13.6 million at the end of the quarter.
Seeking Alpha · 04/01 20:38
Tonix Pharmaceuticals Q4 EPS $(0.86) Beats $(1.55) Estimate, Sales $3.80M Miss $5.75M Estimate
Tonix Pharmaceuticals reported quarterly losses of $0.86 per share. The company reported quarterly sales of $3.80 million which missed the analyst consensus estimate of $5.75 million. Tonix also reported a 75.43 percent increase in sales from the same period last year.
Benzinga · 04/01 20:28
More
About TNXP
Tonix Pharmaceuticals Holding Corp. is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Its development portfolio is focused on central nervous system (CNS) disorders. Its product candidates include Tonmya (TNX-102 SL), TNX-102 SL, TNX-1300, TNX-2900, TNX-1900, TNX-1500, TNX-801 and TNX-1800. TNX-102 SL is for the management of fibromyalgia. Its CNS portfolio includes TNX-1300 (cocaine esterase), a biologic designed to treat cocaine intoxication that has a therapy designation. Its immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. It markets Zembrace SymTouch (sumatriptan injection) 3 mg and Tosymra (sumatriptan nasal spray) 10 mg.

Webull offers Tonix Pharmaceuticals Holding Corp stock information, including NASDAQ: TNXP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TNXP stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TNXP stock methods without spending real money on the virtual paper trading platform.